CMPS or ATAI gives back the majority of June gains within 90 days absent a Phase 3 readout.

Two psychedelic companies — CMPS (Compass Pathways) and ATAI Life Sciences — may see their stock prices rise sharply in June 2026, but that rise will probably collapse within three months if they don't release results from a large, late-stage clinical trial. Stock markets often reward exciting news stories before the science catches up, and when the hype fades, prices drop back down. This cycle has happened repeatedly in the psychedelic investment space.

Narrative is priced in. Without catalysts, momentum reverts. Institutional capital waits for de-risked data, not press-cycle euphoria.